TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06891417: A Phase 1, Randomized, Placebo-controlled, Multi-arm, Study to Evaluate the Safety of a Chlamydia Trachomatis mRNA Vaccine Candidate in Adults

Sponsor: Sanofi · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,058,580

Rescue Site Savings

+$2,674,440

Unlock Full NCT06891417 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06891417 Rescue Dossier →